An Open-Label, Phase 4 Study of Telaprevir, Peginterferon Alfa-2a (Pegasys), and Ribavirin (Copegus) in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C Who Have Not Achieved a Sustained Viral Response With a Prior Course of Interferon-Based Therapy.

Trial Profile

An Open-Label, Phase 4 Study of Telaprevir, Peginterferon Alfa-2a (Pegasys), and Ribavirin (Copegus) in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C Who Have Not Achieved a Sustained Viral Response With a Prior Course of Interferon-Based Therapy.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 05 Aug 2015

At a glance

  • Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 15 Jun 2015 No of arms changed from 4 to 2. Dosage of is changed from 1125mg/day to Telaprevir 750 milligram (mg) tablet 3 times per day for 12 weeks as per ClinicalTrials.gov record.
    • 15 Jun 2015 Status changed from completed to discontinued as per ClinicalTrials.gov record.
    • 11 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top